Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting

Travere Therapeutics, Inc.

Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).
Ten directors elected to serve until 2026 annual meeting; all received majority votes with broker non-votes of ~4.4M.
Advisory vote on named executive officer compensation passed with 71,929,269 votes for.
Ratification of Ernst & Young as independent auditor for FY2025 approved (79,001,421 votes for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.